ribavirina aurobindo 200 mg cápsula
generis farmacêutica, s.a. - ribavirina - cápsula - 200 mg - ribavirina 200 mg - ribavirin - genérico - duração do tratamento: longa duração
imfinzi
astrazeneca ab - durvalumab - carcinoma, pulmão de células não pequenas - agentes antineoplásicos - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).
anusol hc
cadbury brasil indÚstria e comÉrcio de alimentos ltda - anti-hemorroidarios topicos
anusol hc
laboratÓrios pfizer ltda - anti-hemorroidarios topicos
cipro hc
alcon laboratÓrios do brasil ltda. - medicamentos com acao no aparelho auditivo
cipro hc
novartis biociencias s.a - medicamentos com acao no aparelho auditivo
lydisilka
estetra sprl - estetrol monohydrate, drospirenone - contraceptives, oral - hormônios sexuais e moduladores do sistema genital, - contracepção oral. the decision to prescribe lydisilka should take into consideration the individual woman’s current risk factors, particularly those for venous thromboembolism (vte), and how the risk of vte with lydisilka compares with other combined hormonal contraceptives (chcs) (see sections 4. 3 and 4.
eubelle 2 mg + 0.03 mg comprimido revestido por película
lifewell - pharmaceutical & healthcare, lda. - dienogest + etinilestradiol - comprimido revestido por película - 2 mg + 0.03 mg - etinilestradiol 0.03 mg ; dienogest 2 mg - dienogest and ethinylestradiolg03fa15 - dienogest and estrogen - genérico - duração do tratamento: longa duração
ringo 0.015 mg/24 h + 0.12 mg/24 h sistema de libertação vaginal
pharmakern portugal - produtos farmacêuticos, sociedade unipessoal, lda. - etinilestradiol + etonogestrel - sistema de libertação vaginal - 0.015 mg/24 h + 0.12 mg/24 h - etinilestradiol 2.7 mg ; etonogestrel 11.7 mg - vaginal ring with progestogen and estrogeng03aa - progestogens and estrogens, fixed combinations - genérico - duração do tratamento: longa duração
eubelle 2 mg + 0.03 mg comprimido revestido por película
lifewell - pharmaceutical & healthcare, lda. - dienogest + etinilestradiol - comprimido revestido por película - 2 mg + 0.03 mg - etinilestradiol 0.03 mg ; dienogest 2 mg - dienogest and ethinylestradiolg03fa15 - dienogest and estrogen - genérico - duração do tratamento: longa duração